+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Galderma SA (GALD) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 60 Pages
  • October 2024
  • GlobalData
  • Galderma S.A.
  • ID: 4189032
Galderma SA (GALD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Galderma SA (Galderma) provides science-based solutions for skin health. The company’s activities involve the development and distribution of skincare products and medical solutions. Its product portfolio includes prescription drugs, aesthetic solutions, and consumer skincare products. The company’s major brands include Azzalure, Restylane, Sculptra, Cetaphil, and Alastin. Galderma serves its products to a wide range of skin health needs, for the treatment of maintaining healthy skin and rejuvenating aging skin. It distributes through a network of healthcare professionals and retailers, reaching consumers and across various industries. The company has a global presence, operating in over 90 countries. Galderma is headquartered in Lausanne, Lake Geneva, Switzerland.

Galderma SA Key Recent Developments

  • Jul 30, 2024: Galderma’s Relfydess (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
  • Jun 19, 2024: Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
  • Apr 24, 2024: Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth
  • Mar 19, 2024: AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Galderma SA - Key Facts
  • Galderma SA - Key Employees
  • Galderma SA - Key Employee Biographies
  • Galderma SA - Major Products and Services
  • Galderma SA - History
  • Galderma SA - Company Statement
  • Galderma SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Galderma SA - Business Description
  • Product Category: Dermatological Skincare
  • Financials
  • Product Category: Injection Aesthetics
  • Financials
  • Product Category: Therapeutic Dermatology
  • Financials
  • Geographical Segment: International
  • Performance
  • Geographical Segment: USA
  • Performance
  • R&D Overview
  • Galderma SA - Corporate Strategy
  • Galderma SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Galderma SA - Strengths
  • Galderma SA - Weaknesses
  • Galderma SA - Opportunities
  • Galderma SA - Threats
  • Galderma SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Galderma SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Galderma SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 30, 2024: Galderma’s Relfydess (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
  • Jun 19, 2024: Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
  • Apr 24, 2024: Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth
  • Mar 19, 2024: AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
  • Feb 29, 2024: Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
  • Feb 07, 2024: Galderma Launches ‘Next’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
  • Nov 30, 2023: Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines
  • Oct 03, 2023: Ipsen updates on QM-1114 regulatory process
  • Oct 02, 2023: Galderma Announces Progress with RelabotulinumtoxinA Regulatory Submissions
  • Mar 13, 2023: Galderma delivers strong FY 2022 growth driven by innovation and commercial performance
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Galderma SA, Key Facts
  • Galderma SA, Key Employees
  • Galderma SA, Key Employee Biographies
  • Galderma SA, Major Products and Services
  • Galderma SA, History
  • Galderma SA, Subsidiaries
  • Galderma SA, Key Competitors
  • Galderma SA, Ratios based on current share price
  • Galderma SA, Annual Ratios
  • Galderma SA, Interim Ratios
  • Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Galderma SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Galderma SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Galderma SA, Performance Chart (2021 - 2023)
  • Galderma SA, Ratio Charts
  • Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Almirall Hermal GmbH
  • Mylan Pharmaceuticals Inc
  • Merz Aesthetics
  • Aesthetic Medical International Holdings Group Ltd
  • Bausch Health Companies Inc